NASDAQ: CASI | 中文 | Contact Us

CASI News

Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region

March 8, 2021

Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in cancer, and CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, today announced they have entered an exclusive licensing agreement for the development and commercialization of CB-5339, a novel VCP/p97 inhibitor, in mainland China, Taiwan, Hong Kong and Macau.

Read the press release.


CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients

January 28, 2021

Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, said, “We continue to be excited about this anti-FcγRIIB antibody’s potential in restoring rituximab’s activity in NHL patients, and these results provided further encouraging evidence of its potential as a durable and safe treatment alternative. We remain encouraged by its potential application across multiple tumor types in many first line treatments and in refractory settings and are excited to be taking an important step closer to making BI-1206 available to patients and healthcare providers across Greater China.”

Read the press release.
View the presentation.

U.S. FDA-Approved Product

Evomela®

Multiple Myeloma

Clinical Candidates

CNTC19

Hematological Malignancies

BI-1206

Non-Hodgkin's Lymphoma and Solid Tumors

CB-5339

AML, MDS and Solid Tumors

Pre-Clinical Candidates

CID-103

Multiple Myeloma
Learn more about our product pipeline

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More